Miller Anestesia

958 / 2894

69. Rosenbaum HK, Miller JD: Malignant hyperther-
mia and myotonic disorders. Anesthesiol Clin
North Am 20:623-664, 2002.
70. North K: Congenital myopathies. In Engel A, Fran-
zini-Armstrong C (eds): Myology. New York,
McGraw-Hill, 2004, pp 1473-1533.
71. Herman GE, Finegold M, Zhao W, et al: Medical
complications in long-term survivors with X-linked
myotubular myopathy. J Pediatr 134:206-214, 1999.
72. Breslin D, Reid J, Hayes A, Mirakhur RK: Anaesthe-
sia in myotubular (centronuclear) myopathy.
Anaesthesia 55:471-474, 2000.
73. Costi D, van der Walt JH: General anesthesia in an
infant with X-linked myotubular myopathy. Pae-
diatr Anaesth 14:964-968, 2004.
74. García-Aguado R,Núñez M,Tommasi Rosso M,et al:
[Myotubular myopathy (centronuclear) and expected
difficult intubation. Anesthetic management.] Rev
Esp Anestesiol Reanim 41:302-303, 1994.
75. Gottschalk A, Heiman-Patterson T, deQuevedo R
2nd, Quinn PD: General anesthesia for a patient
with centronuclear (myotubular) myopathy. Anes-
thesiology 89:1018-1020, 1998.
76. Schmid E,Johr M,Berger TM: X-linked myotubular
myopathy: Anesthetic management for muscle
biopsy. Paediatr Anaesth 16:218-220, 2006.
77. Tokarz A, Gaszynski T, Gaszynski W, Arkuszewski
P: General anaesthesia with remifentanil and pro-
pofol for a patient with centronuclear (myotubular)
myopathy. Eur J Anaesthesiol 19:842-844, 2002.
78. Dorchies OM, Laporte J, Wagner S, et al: Normal
innervation and differentiation of X-linked myotubu-
lar myopathymuscle cells in a nerve-muscle coculture
system. Neuromuscul Disord 11:736-746, 2001.
79. Raghavan V: Glucose-6-phosphatase deficiency.
2007. Available from
Accessed July 2007.
80. Rake JP, Visser G, Labrune P, et al: Guidelines for
management of glycogen storage disease type
I—European Study on Glycogen Storage Disease
Type I (ESGSD I). Eur J Pediatr 161(Suppl 1)S112-
S119, 2002.
81. Visser G, Rake JP, Labrune P, et al: Consensus gui-
delines for management of glycogen storage disease
type 1b—European Study on Glycogen Storage
Disease Type 1. Eur J Pediatr 161(Suppl 1)S120-
S123, 2002.
82. Kakinohana M, Tokumine J, Shimabukoro T, et al:
[Patient-controlled sedation using propofol for a
patient with von Gierke disease.] Masui 47:1104-
1108, 1998.
83. Kawai T: [Anesthetic management for an emer-
gency operation in a patient with von Gierke
disease.] Masui 54:924-925, 2005.
84. Loonen MC, Busch HF, Koster JF, et al: A family
with different clinical forms of acid maltase defi-
ciency (glycogenosis type II): Biochemical and
genetic studies. Neurology 31:1209-1216, 1981.
85. Engel A, Hirschhorn R, Huie M: Acid maltase defi-
ciency. In Engel A, Franzini-Armstrong C (eds):
Myology. New York, McGraw-Hill, 2004, pp 1559-
1586.
86. AndersonW: Glycogen Storage Disease, Type II. Jan
18, 2006. Available from
Accessed July 2007.
87. Ehlers KH,Hagstrom JW,Lukas DS,et al: Glycogen-
storage disease of the myocardium with obstruction
to left ventricular outflow. Circulation 25:96-109,
1962.
88. Bulkley BH, Hutchins GM: Pompe’s disease presen-
ting as hypertrophic myocardiopathy with Wolff-
Parkinson-White syndrome.AmHeart J 96:246-252,
1978.
89. Weinik M, King F: Acid Maltase Deficiency Myopa-
thy. eMedicine, 2006.
90. Makos MM, McComb RD, Hart MN, Bennett DR:
Alpha-glucosidase deficiency and basilar artery
aneurysm: Report of a sibship. Ann Neurol 22:629-
633, 1987.
91. Gitlin MC,Jahr JS,Margolis MA,McCain J: Is miva-
curium chloride effective in electroconvulsive
therapy? A report of four cases, including a patient
with myasthenia gravis. Anesth Analg 77:392-394,
1993.
92. Kotani N, Hirota K, Anzawa N, et al: Motor and
sensory disability has a strong relationship to
induction dose of thiopental in patients with the
hypertropic variety of Charcot-Marie-Tooth syn-
drome. Anesth Analg 82:182-186, 1996.
93. Ing RJ, Cook DR, Bengur RA, et al: Anaesthetic
management of infants with glycogen storage
disease type II. A physiological approach. Paediatr
Anaesth 14:514-519, 2004.
94. McFarlane HJ, Soni N: Pompe’s disease and anaes-
thesia. Anaesthesia 41:1219-1224, 1986.
95. Mohiddin SA, Fananapazir L: Systolic compression
of epicardial coronary and intramural arteries in
children with hypertrophic cardiomyopathy. Tex
Heart Inst J 29:290-298, 2002.
96. DiMauro S, Bonilla E: Mitochondrial encephalom-
yopathies. In Engel A, Franzini-Armstrong C (eds):
Myology. New York, McGraw-Hill, 2004, pp 1623-
1662.
97. Siciliano G,Volpi L, Piazza S, et al: Functional diag-
nostics in mitochondrial diseases. Biosci Rep 27:53-
67, 2007.
98. Wisely NA, Cook PR: General anaesthesia in a man
with mitochondrial myopathy undergoing eye
surgery. Eur J Anaesthesiol 18:333-335, 2001.
99. Mehndiratta MM, Agarwal P, Tatke M, Krishma-
murthy M: Neurological mitochondrial cytopathies.
Neurol India 50:162-167, 2002.
100. Wallace JJ, Perndt H, Skinner M: Anaesthesia and
mitochondrial disease. Paediatr Anaesth 8:249-254,
1998.
101. Swash M, Schwartz MS, Sargeant MK: The signifi-
cance of ragged-red fibres in neuromuscular disease.
J Neurol Sci 38:347-355, 1978.
102. Shipton EA, Prosser DO: Mitochondrial myopa-
thies and anaesthesia. Eur J Anaesthesiol 21:173-
178, 2004.
103. Levy E, Muravchick S: Mitochondrial diseases. In
Fleisher L (ed): Anesthesia and Uncommon Disea-
ses. Philadelphia, Saunders Elsevier, 2006, pp 455-
467.
104. James RH: Thiopentone and ophthalmoplegia plus.
Anaesthesia 40:88, 1985.
105. James RH: Induction agent sensitivity and ophthal-
moplegia plus. Anaesthesia 41:216, 1986.
106. Driessen J,Willems S, Dercksen S, et al: Anesthesia-
related morbidity and mortality after surgery for
muscle biopsy in children with mitochondrial
defects. Paediatr Anaesth 17:16-21, 2007.
107. Burns AM, Shelly MP: Anaesthesia for patients with
mitochondrial myopathy. Anaesthesia 44:975-977,
1989.
108. Kelly A,O’Connor M: Mitochondrial myopathy and
anaesthesia. Anaesthesia 45:596, 1990.
109. Ramchandra DS, Anisya V, Gourie-Devi M: Keta-
mine monoanaesthesia for diagnostic muscle biopsy
in neuromuscular disorders in infancy and child-
hood: Floppy infant syndrome. Can J Anaesth
37:474-476, 1990.
110. Guasch E, Civantos B, Aguilar JM, et al: Progressive
external ophthalmoplegia and ambulatory remifen-
tanil-propofol based anaesthesia. Anaesthesia
58:607-608, 2003.
111. Stowe DF, Kevin LG: Cardiac preconditioning by
volatile anesthetic agents: A defining role for altered
mitochondrial bioenergetics.Antioxid Redox Signal
6:439-448, 2004.
112. Stadnicka A, Marinovic L, Ljubkovic M, et al: Vola-
tile anesthetic–induced cardiac preconditioning.
J Anesth 21:212-219, 2007.
113. Lauwers MH, Van Lersberghe C, Camu F: Inhala-
tion anaesthesia and the Kearns-Sayre syndrome.
Anaesthesia 49:876-878, 1994.
114. Morgan PG, Hoppel CL, Sedensky MM: Mitochon-
drial defects and anesthetic sensitivity. Anesthesio-
logy 96:1268-1270, 2002.
115. Allen GC: Bispectral index andmitochondrial myopa-
thies.Anesthesiology 98:282, author reply 283, 2003.
116. Frei FJ, Haemmerle MH, Brunner R, Kern C:
Minimum alveolar concentration for halothane in
children with cerebral palsy and severe mental
retardation. Anaesthesia 52:1056-1060, 1997.
117. Naguib M,el Dawlatly AA,Ashour M,al-Bunyan M:
Sensitivity to mivacurium in a patient with mito-
chondrial myopathy. Anesthesiology 84:1506-1509,
1996.
118. Finsterer J, Stratil U, Bittner R, Sporn P: Increased
sensitivity to rocuronium and atracurium in mito-
chondrial myopathy. Can J Anaesth 45:781-784,
1998.
119. Sharma AD, Erb T, Schulman SR, et al: Anaesthetic
considerations for a child with combined Prader-
Willi syndrome and mitochondrial myopathy. Pae-
diatr Anaesth 11:488-490, 2001.
120. D’Ambra MN, Dedrick D, Savarese JJ: Kearns-Sayre
syndrome and pancuronium-succinylcholine-indu-
ced neuromuscular blockade. Anesthesiology
51:343-345, 1979.
121. Wiesel S, Bevan JC, Samuel J, Donati F:Vecuronium
neuromuscular blockade in a child with mitochon-
drial myopathy. Anesth Analg 72:696-699, 1991.
122. Rowe RW, Helander E: Anesthetic management of
a patient with systemic carnitine deficiency. Anesth
Analg 71:295-297, 1990.
123. Rosaeg OP, Morrison S, MacLeod JP: Anaesthetic
management of labour and delivery in the partu-
rient with mitochondrial myopathy. Can J Anaesth
43:403-407, 1996.
124. Hsiao PN, Cheng YJ, Tseng HC, et al: Spinal anes-
thesia in MELAS syndrome: A case with mitochon-
drial myopathy, encephalopathy, lactic acidosis and
stroke-like episodes. Acta Anaesthesiol Sin 38:
107-110, 2000.
125. Sasano N, Fujita Y, So M, et al: Anesthetic manage-
ment of a patient with mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like epi-
sodes (MELAS) during laparotomy. J Anesth 21:
72-75, 2007.
126. Farag E,Argalious M, Narouze S, et al: The anesthe-
tic management of ventricular septal defect (VSD)
repair in a child with mitochondrial cytopathy. Can
J Anaesth 49:958-962, 2002.
127. Vincent A, Palace J, Hilton-Jones D: Myasthenia
gravis. Lancet 357:2122-2128, 2001.
128. Lindstrom JM: Acetylcholine receptors and myas-
thenia. Muscle Nerve 23:453-477, 2000.
129. Eisenkraft JB, Book WJ, Mann SM, et al: Resistance
to succinylcholine in myasthenia gravis: A dose-
response study. Anesthesiology 69:760-763, 1988.
130. Baraka A: Suxamethonium block in the myasthenic
patient. Correlation with plasma cholinesterase.
Anaesthesia 47:217-219, 1992.
131. Seigne RD, Scott RP: Mivacurium chloride and
myasthenia gravis. Br J Anaesth 72:468-469, 1994.
132. Kim JM, Mangold J: Sensitivity to both vecuronium
and neostigmine in a sero-negative myasthenic
patient. Br J Anaesth 63:497-500, 1989.
958 Control de la anestesia III